$13.07
2.02% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US05380C1027
Symbol
RCEL
Sector

AVITA Therapeutics Stock price

$13.07
+2.94 29.02% 1M
+4.97 61.36% 6M
-0.65 4.74% YTD
+2.22 20.46% 1Y
-1.74 11.75% 3Y
-26.38 66.87% 5Y
+5.47 71.97% 10Y
NYSE, Closing price Mon, Nov 25 2024
-0.27 2.02%
ISIN
US05380C1027
Symbol
RCEL
Sector

Key metrics

Market capitalization $324.70m
Enterprise Value $325.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.43
P/S ratio (TTM) P/S ratio 5.41
P/B ratio (TTM) P/B ratio 28.03
Revenue growth (TTM) Revenue growth 32.24%
Revenue (TTM) Revenue $60.04m
EBIT (operating result TTM) EBIT $-137.99m
Free Cash Flow (TTM) Free Cash Flow $-59.91m
Cash position $44.41m
EPS (TTM) EPS $-2.23
P/E forward negative
P/S forward 4.70
EV/Sales forward 4.72
Short interest 4.62%
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a AVITA Therapeutics forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a AVITA Therapeutics forecast:

Buy
63%
Hold
38%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
60 60
32% 32%
100%
- Direct Costs 8.61 8.61
17% 17%
14%
51 51
35% 35%
86%
- Selling and Administrative Expenses 166 166
187% 187%
276%
- Research and Development Expense 22 22
28% 28%
37%
-137 -137
268% 268%
-228%
- Depreciation and Amortization 1.21 1.21
18% 18%
2%
EBIT (Operating Income) EBIT -138 -138
258% 258%
-230%
Net Profit -57 -57
70% 70%
-95%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
about 16 hours ago
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1...
Neutral
GlobeNewsWire
14 days ago
VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd.
Neutral
Seeking Alpha
17 days ago
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potte...
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 207
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today